Celldex Therapeutics, Inc. (CLDX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Celldex Therapeutics is a biopharmaceutical company focused on developing antibody-based treatments for allergic, inflammatory, and autoimmune disorders. The company's primary asset is barzolvolimab (CDX-0159), a monoclonal antibody targeting the KIT receptor, currently in Phase 3 development for Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). The company also has a bispecific antibody candidate, CDX-622, in Phase 1.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $15 | $695 |
| Net Loss | $(78,685) | $(53,796) |
| Net Loss Per Share (Basic & Diluted) | $(1.18) | $(0.81) |
| Research & Development Expenses | $73,001 | $52,614 |
| General & Administrative Expenses | $11,449 | $10,820 |
| Cash, Cash Equivalents & Marketable Securities | $451,458 | $518,058 |
| Net Cash Used in Operating Activities | $(65,588) | $(54,372) |
| Total Assets | $511,254 | $582,983 |
| Total Liabilities | $55,028 | $55,818 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped 98% to $15,000, primarily due to a decrease in contract and grant revenue from Rockefeller University ($15,000 vs. $645,000 in Q1 2025).
- Increased Net Loss: Net loss widened by 46% to $78.7 million, driven by a 39% increase in R&D expenses and a 36% decrease in investment income.
- R&D Spend Surge: R&D expenses increased by $20.4 million, largely attributed to accelerated clinical trial and contract manufacturing costs for barzolvolimab. Product development costs specifically rose by $18.0 million.
- Liquidity Position: While cash and marketable securities decreased by approximately $66.6 million during the quarter due to operating burn and net investment activity, the company completed an underwritten public offering in April 2026 (post-period) raising approximately $323.9 million.
Outlook, Guidance, and Risks
- Clinical Milestones:
- CSU Phase 3: Enrollment of 1,939 patients completed in February 2026. Topline data expected in Q4 2026. A Biologics License Application (BLA) is planned for 2027 assuming positive data.
- CIndU Phase 3: Initiated in December 2025; enrollment ongoing.
- Prurigo Nodularis (PN) & Atopic Dermatitis (AD): Phase 2 enrollment completed in late 2025/early 2026. Topline data expected in Summer 2026 and late 2026, respectively.
- CDX-622: Phase 1a enrollment completed in January 2026. Data from multiple ascending doses expected in Q3 2026.
- Liquidity Outlook: Management believes current cash resources, combined with the April 2026 offering proceeds, are sufficient to fund operations through 2028. However, future funding may be required depending on the timing of a potential $52.5 million milestone payment related to the Kolltan acquisition settlement.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital on acceptable terms, and the potential dilution from future equity offerings. The company maintains a full valuation allowance on deferred tax assets due to recurring losses.
Investor Verification Checklist
- Verify the timeline and expectations for the Q4 2026 topline data release for the barzolvolimab CSU Phase 3 trials.
- Confirm the details of the April 2026 underwritten public offering (11.9 million shares, ~$324M net proceeds) and its impact on share count and dilution.
- Monitor the status of the $52.5 million contingent milestone payment obligation under the Kolltan Settlement Agreement and the company's election to pay in cash or stock.
- Review the burn rate trajectory given the 39% increase in R&D spend and the expectation of continued high product development costs.
- Assess the progress of the CDX-622 bispecific program as a potential pipeline diversifier beyond barzolvolimab.